Understanding and Anticipating Lag-Time Bias in Cost-Effectiveness Studies: The Role of Time in Cost-Effectiveness Analysis

被引:6
作者
van de Wetering, Gijs [1 ]
Rikkert, Marcel Olde [2 ]
van der Wilt, Gert Jan [1 ]
Adang, Eddy [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Geriatr, NL-6500 HB Nijmegen, Netherlands
关键词
Cost-effectiveness; Time; Inefficiencies; Bios; PARTIAL ILEAL BYPASS; NISSEN FUNDOPLICATION; ECONOMIC-EVALUATION; LEARNING-CURVE; HEALTH-CARE; PREVENTION; DISEASE;
D O I
10.1017/S0266462314000762
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Timely provision of information on the cost-effectiveness of innovations in health care becomes more and more important, resulting in increasing pressure on researchers to provide proof of cost-effectiveness in a short time frame. However, most of these innovations require considerable time and effort to optimally implement leading to a biased "steady state" cost-effectiveness outcome. As decision makers in health care predominantly have a short-term focus, the discrepancy between short-term study outcomes and long-term cost-effectiveness may very well lead to misguided decisions about the adoption of innovations in health care. Methods: Factors such as learning effects, capacity constraints, and delayed time to benefit are all related to a short-run timeframe and result in inefficiencies during the implementation of an innovation. These factors and the mechanisms by which they influence the cost-effectiveness outcome are explained for three different types of healthcare innovations. Results: As standard cost-effectiveness analysis assumes costs and effects to behave constant and representative for an innovation's entire economic lifetime, resulting cost-effectiveness outcomes might give a biased, and often overly pessimistic, reflection of the actual cost-effectiveness of an innovation. This is further amplified by the fact that short-run inefficiencies are most prevalent and impactful during an innovation's earliest stage of operation. Conclusions: This study advocates to carefully take into account the different factors contributing to lag-time bias in the design and analysis of cost-effectiveness studies, and to communicate potential biases due to short-run inefficiencies to all stakeholders involved in the decision making process.
引用
收藏
页码:608 / 611
页数:4
相关论文
共 20 条
  • [1] Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions
    Adang, E
    Voordijk, L
    van der Wilt, GJ
    Ament, A
    [J]. HEALTH POLICY, 2005, 74 (02) : 146 - 156
  • [2] Learning curve models and applications: Literature review and research directions
    Anzanello, Michel Jose
    Fogliatto, Flavio Sanson
    [J]. INTERNATIONAL JOURNAL OF INDUSTRIAL ERGONOMICS, 2011, 41 (05) : 573 - 583
  • [3] LEARNING-CURVES IN MANUFACTURING
    ARGOTE, L
    EPPLE, D
    [J]. SCIENCE, 1990, 247 (4945) : 920 - 924
  • [4] Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomised clinical trial
    Bais, JE
    Bartelsman, JFWM
    Bonjer, HJ
    Cuesta, MA
    Go, PMNYH
    Klinkenberg-Knol, EC
    van Lanschot, JJB
    Nadorp, JHSM
    Smout, AJPM
    van der Graaf, Y
    Gooszen, HG
    [J]. LANCET, 2000, 355 (9199) : 170 - 174
  • [5] Impact of Surgeon Experience on 5-Year Outcome of Laparoscopic Nissen Fundoplication
    Broeders, Joris A. J. L.
    Draaisma, Werner A.
    Rijnhart-de Jong, Hilda G.
    Smout, Andre J. P. M.
    van Lanschot, Jan J. B.
    Broeders, Ivo A. M. J.
    Gooszen, Hein G.
    [J]. ARCHIVES OF SURGERY, 2011, 146 (03) : 340 - 346
  • [6] Brown TJ, 2006, HEALTH TECHNOL ASSES, V10, P1
  • [7] EFFECT OF PARTIAL ILEAL BYPASS-SURGERY ON MORTALITY AND MORBIDITY FROM CORONARY HEART-DISEASE IN PATIENTS WITH HYPERCHOLESTEROLEMIA - REPORT OF THE PROGRAM ON THE SURGICAL CONTROL OF THE HYPERLIPIDEMIAS (POSCH)
    BUCHWALD, H
    VARCO, RL
    MATTS, JP
    LONG, JM
    FITCH, LL
    CAMPBELL, GS
    PEARCE, MB
    YELLIN, AE
    EDMISTON, WA
    SMINK, RD
    SAWIN, HS
    CAMPOS, CT
    HANSEN, BJ
    TUNA, N
    KARNEGIS, JN
    SANMARCO, ME
    AMPLATZ, K
    CASTANEDAZUNIGA, WR
    HUNTER, DW
    BISSETT, JK
    WEBER, FJ
    STEVENSON, JW
    LEON, AS
    CHALMERS, TC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) : 946 - 955
  • [8] CLINICAL ANGIOGRAPHIC REGRESSION OF ATHEROSCLEROSIS AFTER PARTIAL ILEAL BYPASS
    BUCHWALD, H
    MOORE, RB
    RUCKER, RD
    AMPLATZ, K
    CASTANEDA, WR
    FRANCOZ, RA
    PASTERNAK, RC
    VARCO, RL
    [J]. ATHEROSCLEROSIS, 1983, 46 (01) : 117 - 128
  • [9] Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland
    Chancellor, JVM
    Hunsche, E
    de Cruz, E
    Sarasin, FP
    [J]. PHARMACOECONOMICS, 2001, 19 (01) : 59 - 75
  • [10] Economic evaluation under managed competition: Evidence from the UK
    Drummond, M
    Cooke, J
    Walley, T
    [J]. SOCIAL SCIENCE & MEDICINE, 1997, 45 (04) : 583 - 595